金吾财讯 | 据港交所7月30日披露，丹诺医药向港交所主板提交上市申请，中信证券、农银国际为联席保荐人。
公司是一家临近商业化阶段的生物科技公司，专注于发现、开发及商业化差异化的创新药产品，以解决细菌感染及细菌代谢相关疾病领域的未被满足临床需求。
公司核心产品利福特尼唑（TNP-2198）是自1982年发现幽门螺杆菌以来，全球首个且截至最后实际可行日期唯一治疗该细菌感染的新分子实体候选药物，公司正在为利福特尼唑实施明确的临床开发及商业化策略。
财务方面，公司于2023年、2024年及2025年首季分别录得净亏损1.91亿元、1.46亿元及3800万元人民币，对应同期分别录得研发开支1.08亿元、6983.8万元、1320.5万元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.